欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells

发布时间:2026-01-06

Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells

Priscilla N. Kelly, Aleksandar Dakic, Jerry M. Adams, Stephen L. Nutt, and Andreas Strasser
Science 20 July 2007: 337.
Many of the lymphoma and leukemia cells in mice can seed new tumors, a result inconsistent with the hypothesis that tumor growth is driven by rare cancer stem cells.
Abstract »|   Full Text »|   PDF »|   Supporting Online Material »|  

 

 

作者简介:

Dr. Andreas Strasser

Molecular Genetics of Cancer Division

 

Research Overview:

Dr Strasser and his team are investigating the control of apoptosis, the cell death program essential for development and homeostasis. By using transgenic mice over-expressing the cell death inhibitor Bcl-2 and knock-out mice lacking one of its antagonists, they demonstrated that abnormalities in the control of apoptosis can cause autoimmune disease or cancer and render tumour cells refractory to anti-cancer therapy. Dr Strasser and his co-workers established that mammalian cells have two distinct signalling pathways leading to apoptosis, one triggered by ligation of cell surface "death receptors" and the other by certain developmental cues, cytokine deprivation or stress signals. Using genetically modified mice they could determine signalling mechanisms that are responsible for killing useless or potentially dangerous at the different checkpoints during lymphocyte development. Using biochemical and molecular biology techniques, Dr Strasser and his team discovered novel regulators that are essential for initiation of programmed cell death and showed that they function as sentinels for damage to various vital intra-cellular structures, such as the cytoskeleton. These discoveries have major implications for cancer research, developmental biology and immunology and suggest novel therapeutic strategies for tumours, autoimmunity and degenerative diseases.
Current research interests include identification of the signalling pathways that mediate developmentally programmed cell death in mammals and those that are responsible for chemotherapy-induced killing of cancer cells, with the goal to develop improved strategies for treatment of cancer and autoimmune diseases.

 

 

上一篇:西亚试剂:美开发自体免疫疾病新疗法 可诱导出致病炎症细胞
下一篇:西亚试剂:上海药物所发现靶向酪氨酸激酶ALK的二代小分子抑制剂
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4